Knowledge About Vaccines and Willingness to Participate in Preventive HIV Vaccine Trials: A Population-Based Study, Rakai, Uganda

Kiwanuka, Noah MB, ChB, MPH*; Robb, Merlin MD†; Kigozi, Godfrey MB, ChB, MPH*; Birx, Deborah MD, MS‡; Philips, James MD, PhD†; Wabwire-Mangen, Fred MD, MPH, PhD§; Wawer, Maria J. MD, MSc¶; Nalugoda, Fred Bstat, MHS*; Sewankambo, Nelson K.**; Serwadda, David‡; Gray, Ronald H. MBBS, MSc††

JAIDS Journal of Acquired Immune Deficiency Syndromes:
Epidemiology And Social Science

The purpose of the study was to assess knowledge and beliefs regarding vaccines and willingness to participate in HIV vaccine trials. A baseline survey assessed knowledge and attitudes toward vaccination and potential HIV vaccines among 14,177 participants aged 15–49 years, in a population cohort. Willingness to participate in HIV-preventive vaccine trials was assessed during a follow-up survey 10 months later after providing community education on HIV vaccines. Knowledge of the preventive utility of vaccines was high (71%), but higher in men than women (P < 0.001), and increased with education levels (P < 0.001). Vaccines were considered appropriate for children and women (99 and 88%, respectively), but not for adult men (28%). Participants felt that adolescents were the most appropriate subjects for HIV preventive vaccine trials (93.7%) but also thought that HIV-positive persons were eligible for trials (60.2%), and only 20% thought a preventive vaccine could help control HIV. HIV vaccine awareness increased from 68% at baseline to 81% at follow-up (P < 0.001). Willingness to participate in HIV-preventive vaccine trials was 77%. Vaccine knowledge and willingness to participate in trials are high in this population. However, there still is need for education on the potential role of preventive HIV vaccines in the control of the epidemic and the importance of vaccination for men, especially in the context of an HIV vaccine.

Author Information

From the *Rakai Project, Uganda Virus Research Institute, Entebbe; †Henry M. Jackson Foundation, Rockville, MD; ‡Walter Reed Army Institute of Research, Washington, DC; §Institute of Public Health, Makerere University, Kampala, Uganda; ¶Center for Population and Family Health, Columbia University, New York, NY; **Department of Medicine, Faculty of Medicine, Makerere University, Kampala, Uganda; and ††Bloomberg School of Public Health, Johns Hopkins University, Baltimore, MD.

Received for publication August 6, 2003; accepted November 11, 2003.

This study was funded through the Department of the Army, United States Army Medical Research and Material Command Cooperative Agreement DAMD17-98-2-8007 and the Henry M. Jackson Foundation and a grant 5D43TW00010 from the Fogarty Foundation. The content does not necessarily reflect the position or policies of the US Government, the Department of Army, MRCM, or the Foundation.

Reprints: Ronald H. Gray, Department of Population and Family Health Sciences, Bloomberg School of Public Health, Johns Hopkins University, Room W4030, 615 N. Wolfe Street, Baltimore, MD, 21205 (e-mail:

Article Outline

An HIV-preventive vaccine is urgently needed to control the HIV pandemic, particularly in developing countries where the prevalence and incidence of HIV are high, but resources for prevention and care are limited. 1–3 Given the genetic variability of HIV, the geographic differences in subtypes and negative results of the first phase 3 efficacy trial, 4 it is probable that multiple trials will be needed.

Knowledge of and attitudes toward HIV vaccines are among the factors that may influence participation in trials and the eventual acceptability of efficacious vaccines. 5–9 Most studies have been conducted in selected populations of gay men, injection drug users, commercial sex workers, and college students. 5–15 However, there is no information on willingness to participate (WTP) in HIV vaccine trials from general population studies particularly in developing countries, 16,17 which represent an important population for vaccine efficacy testing. To address this issue, we assessed knowledge and beliefs regarding HIV vaccines as well as WTP in vaccine trials in a rural population cohort in Rakai, Uganda, with an HIV prevalence of 15% and incidence of 1.4/100 person-years. Rakai district is a potential site for phase 3 HIV-preventive vaccine trials.

Back to Top | Article Outline


Between April 1999 and March 2002, we conducted the Community HIV Epidemiological Research study (CHER) to assess the suitability of Rakai district for future phase 3 HIV vaccine trials. The study was a continuation of a community cohort established in 1994 for the sexually transmitted diseases (STD) control study that ended in 1999. 18,19

Consenting adults aged 15–49 years, resident in 56 communities in Rakai, were enrolled and visited in the home every 10 months, during which a questionnaire was administered in privacy by same-sex interviewers, and venous blood was collected for HIV-1 testing. All questions were translated in the local language (Luganda) and pretested. Participants who provided blood were encouraged to receive free voluntary counseling and test (VCT) results provided by community-based counselors. Prebaseline health education was provided on study objectives and HIV/STD prevention strategies focusing mainly on safe sex behaviors including faithfulness (i.e., monogamy), abstinence, or condom use, and VCT.

At the baseline, CHER survey data were collected on knowledge and beliefs about vaccination, HIV/STD risk behaviors, and participants' perception of the severity of the AIDS epidemic in Rakai and methods for controlling it. For data collected on receipt of previous vaccination, reasons for use of vaccines, concerns about vaccine safety, eligibility for vaccination, and awareness of potential HIV vaccines, the questionnaire used unprompted questions and allowed for an “other” category for nonspecified responses, which were recorded verbatim.

Between baseline and follow-up surveys, education on potential HIV-preventive vaccines was provided. The topics included the need for an HIV-preventive vaccine, the research/testing processes (including use of placebo) that any potential vaccine would undergo, and the need to prepare populations for future HIV-preventive vaccine research. It was emphasized that CHER was neither a vaccine trial nor a preparatory phase for an available HIV vaccine construct.

During the CHER follow-up survey, we assessed WTP in HIV vaccine trials, eligibility for participation in trials, and knowledge of potential HIV vaccines. Additionally, we evaluated participants' awareness of the phase 1 ALVAC™-HIV trial in Kampala, Uganda. 9

We determined the frequencies of vaccine knowledge and attitudes by sociodemographic and behavioral characteristics, and differences were assessed by χ2 tests. Previous studies suggest that sociodemographic characteristics, risk behavior, and self-perception of HIV risk are associated with WTP. 5,7–9,16 We determined the rate of WTP and examined the association between WTP and sociodemographic characteristics, risk behaviors, self-perception of HIV risk, previous participation in VCT, and awareness of potential HIV vaccines. Log-binomial regression models were used to estimate the adjusted rate ratios (RRs) and 95% CIs of factors associated with WTP. 20 Models were adjusted for age, gender, and statistically significant covariates identified in univariate analyses. Statistical analysis was conducted using Stata 7.0 (Stata Corp.; College Station, TX).

Back to Top | Article Outline


Knowledge of and Attitudes Toward Vaccines at the Baseline Survey

Table 1 shows knowledge and attitudes toward vaccines at the baseline survey. Ninety-nine percent were aware of vaccination, 83% gave a history of previous vaccination, and 87% reported polio as a childhood immunizable disease. There were no gender or age differences in awareness of vaccination. However, adolescents and male participants were less likely to report receipt of previous vaccination (P < 0.001). Knowledge of the utility of vaccines was high (71%) but was notably higher in men than women (78.8 and 67.6%, respectively, P < 0.001). Vaccine knowledge increased with education levels (P < 0.001). Eighty-three percent of the participants expressed no concerns about vaccine safety, 7.8% thought vaccines might be lethal, and 2.6% reported that vaccines cause fever/illness. Concerns about vaccine safety were significantly higher among men and older participants (P < 0.001) and increased with higher levels of education (P < 0.001).

Most participants thought children and women (99 and 88%, respectively) were eligible for vaccination, but only 28% thought that men were eligible. Moreover, 61% of male participants thought men should not receive vaccines. Only 12% considered HIV/AIDS a “very serious” problem in Rakai despite the high HIV prevalence and the HIV-attributable mortality in this population. 21 Regarding methods of controlling HIV, 41% reported faithfulness (monogamy), and only 20% reported use of an HIV vaccine. Men were more likely than women (23 vs. 17%, respectively, P < 0.001) and adolescents were less likely than adults (16.2 vs. 20.8%, P < 0.001) to report use of a vaccine as a means of preventing HIV. Sixty-eight percent were aware of potential HIV vaccines and 41% knew about Uganda's first HIV vaccine trial. 9

Back to Top | Article Outline

Knowledge and Attitudes Toward HIV Vaccines at Follow-up

Of the 14,177 participants interviewed at baseline, 10,312 (73%) were reinterviewed at the follow-up survey. We assessed the impact of a community-based education program on knowledge of potential HIV vaccines. Awareness of HIV vaccines increased from 68% at baseline to 81% at follow-up (P < 0.001), but knowledge of HIV vaccine testing in Uganda remained unchanged (41% at both interviews). Information on HIV vaccines came mainly from the Rakai project education program (74%); other sources included radio/television (15%) and hospitals/clinics/newspapers (~10%). It is noteworthy that participants believed that HIV-infected and HIV-uninfected subjects were appropriate for participation in trials (60.2 and 69.8%, respectively), despite the education program's emphasis on preventive vaccines.

Back to Top | Article Outline
Willingness to Participate in Future Vaccine Trials

At the follow-up survey, 77% of participants indicated willingness to participate in future HIV vaccine trials, and as shown in Table 2, WTP did not differ by sociodemographic characteristics. On univariate analysis, self-perception of HIV risk, previous receipt of VCT, awareness of potential HIV-preventive vaccines, and receipt of information on HIV vaccines were significantly associated with WTP. These covariates plus age and gender were incorporated in the multivariate regression model. After adjustment, only self-perception of HIV risk (adjusted RR = 1.12; 95% CI, 1.10–1.15) and receipt of education on vaccines (adjusted RR = 1.03; 95% CI, 1.01–1.06) were significantly associated with WTP.

Back to Top | Article Outline


Consistent with other studies, 9,13,16 we found a high level of knowledge of vaccination in this rural Ugandan population and this probably reflects the high childhood immunization coverage in the district 22 and nation-wide immunization campaigns. However, most participants, including more than half of the men, thought that vaccines were only useful for children and women. Many participants thought men were not eligible for vaccination, probably because vaccination in this population is mainly for children and pregnant women. If unchanged, this belief may affect participation of men in future HIV vaccine trials and the eventual acceptability of a successful vaccine. Vaccine trials will require comprehensive education, and our strategy of using village-based health education meetings resulted in a significant increase in the level of awareness of potential HIV vaccines from 68% at baseline to 81% at follow-up. However, fewer than half the participants were aware of the phase 1 ALVAC-HIV trial in Kampala. 23 In rural populations where illiteracy levels are high and access to media is low, education is probably best conducted via face-to-face village meetings.

With an HIV prevalence of 15% and almost 2 decades of experience with the AIDS epidemic in Rakai district, only 12% considered AIDS to be a “very serious problem,” and knowledge of the potential utility of an HIV-preventive vaccine was low (20%). This probably reflects the abatement of the HIV epidemic in Uganda, which has received considerable publicity that may be engendering growing complacency. There is need for more education on the persistence of the HIV/AIDS epidemic, the need to prevent transmission, and the potential role of HIV-preventive vaccines.

This population-based study showed a high level of WTP in HIV vaccine trials (77%), which is comparable to levels found in the Ugandan military (79%) but higher than levels in North American gay men/injection drug users (46%) and in commercial sex workers or STD clinic attendees in northern Thailand (~25%). 9,16,24 WTP did not vary substantially by sociodemographic characteristics, self-perceived risk of HIV, or knowledge of vaccines. Therefore, future vaccine trials may not require targeting of population subgroups.

The limitations of our data are that questions regarding WTP were hypothetical, and the Rakai cohort has been under surveillance for several years so attitudes toward participation in research activities may differ from those in other populations. Additionally, WTP was assessed after general community education rather than following an HIV vaccine trial-specific education program.

In conclusion, the Rakai population has a high level of knowledge of vaccination and WTP in HIV vaccine trials. However, there still is a need for more education, particularly on the severity of the HIV/AIDS epidemic and the potential utility of HIV-preventive vaccines.

Back to Top | Article Outline


The authors appreciate the contribution of study participants, project staff, and Dr. S.K. Sempala, Uganda Virus Research Institute.

Back to Top | Article Outline


1. United Nations Programme on HIV/AIDS, World Health Organization. AIDS Epidemic Update: December, 1999. Geneva: WHO; 1999. Document UNAIDS/99.53E.
2. Berkley S. HIV vaccine development for the world: an idea whose time has come. AIDS Res Hum Retroviruses. 1998;14(suppl 3):S191–S196.
3. Esparza J, Bhamarapravati N. Accelerating the development and future availability of HIV-1 vaccines: why, when, where, and how?Lancet. 2000;355:2061–2066.
4. VaxGen. VaxGen announces initial results of its phase III AIDS vaccine trial. Press release February 24, 2003. Available at: Last accessed October 20, 2003.
5. Koblin BA, Holte S, Lenderking B, et al. Readiness for HIV vaccine trials: changes in willingness and knowledge among high-risk populations in the HIV Network for Prevention Trials. J Acquir Immune Defic Syndr. 2000;24:451–457.
6. Liau A, Zimet GD. Undergraduates' perception of HIV immunization: attitudes and behaviours as determining factors. Int J STD AIDS. 2000;11:445–450.
7. MacQueen KM, Vanichseni S, Kitayaporn D, et al. Willingness of injection drug users to participate in an HIV vaccine efficacy trial in Bangkok, Thailand. J Acquir Immune Defic Syndr. 1999;21:243–251.
8. Hays RB, Kegeles SM. Factors related to the willingness of young gay men to participate in preventive HIV vaccine trials. J Acquir Immune Defic Syndr Hum Retrovirol. 1999;20:164–171.
9. McGrath JW, George K, Svilar G, et al. Knowledge about vaccine trials and willingness to participate in an HIV/AIDS vaccine study in the Ugandan military. J Acquir Immune Defic Syndr. 2001;27:381–388.
10. Douglas JM Jr, Judson FM, Parks JP, et al. Participation of homosexual/bisexual men in preventive HIV trials: baseline attitudes and concerns and predicted behaviors during trials. AIDS Res Hum Retroviruses. 1994;10:S257–S260.
11. MacQueen KM, Buchbinder S, Douglas JM, et al. The decision to enroll in HIV efficacy trials: concerns elicited from gay men at increased risk of infection. AIDS Res Hum Retroviruses. 1994;10:S261–S264.
12. Vlahov D, Astemborski J, Solomon L, et al. Interest in HIV vaccines among injection drug users in Baltimore, MD. AIDS Res Hum Retroviruses. 1994;10:265–268.
13. Hom D, Johnson JL, Mugyeni P, et al. HIV-1 risk and vaccine acceptability in the Uganda military. J Acquir Immune Defic Syndr Hum Retrovirol. 1997;15:375–380.
14. McGrath JW, Mafigiri D, Kamya M, et al. Developing AIDS vaccine trials educational programs in Uganda. J Acquir Immune Defic Syndr. 2001;26:176–181.
15. Jackson DJ, Martin HL Jr, Bwayo JJ, et al. Acceptability of HIV vaccine trials in high-risk heterosexual cohorts in Mombasa, Kenya. AIDS. 1995;9:1279–1283.
16. Celantano DD, Beyrer C, Natpratan C, et al. Willingness to participate in AIDS vaccine trials among high-risk populations in northern Thailand. AIDS. 1995;9:1079–1083.
17. Nelson KE, Suriyanon V, Taylor E, et al. The incidence of HIV-1 infections in village populations in northern Thailand. AIDS. 1994;8:951–955.
18. Wawer MJ, Sewankambo NK, Serwadda D, et al. Randomized community trial of intensive STD control for AIDS prevention, Rakai, Uganda. AIDS. 1998;12:1211–1225.
19. Wawer MJ, Sewankambo NK, Serwadda D, et al. Results of the Rakai community trial of intensive STD control for AIDS prevention. Lancet. 1999;353:525–535.
20. Skov T, Deddens J, Peterson MR, et al. Prevalence proportion ratios: estimation and hypothesis testing. Int J Epidemiol. 1998;27:91–95.
21. Sewankambo NK, Gray RH, Saifuddin A. et al. Mortality associated with HIV infection in rural Rakai district, Uganda. AIDS. 2000;14:2391–2400.
22. Rakai District Development Plan (1994/95–1998/99), vol. 1. Policy Guidelines: Rakai District Administration, Rakai, Uganda.
23. Mugerwa RD, Kaleebu P, Mugenyi P, et al. First trial of HIV vaccine in Africa: Ugandan experience. BMJ. 2002;324:226–229.
24. Strauss RP, Sengupta S, Kegeles S. McLellan, et al. Willingness to volunteer in future preventive HIV vaccine trials: issues and perspectives from three U.S. communities. JAIDS. 2001;26:63–71.

Cited By:

This article has been cited 1 time(s).

HIV-1 subtypes and differences in heterosexual HIV transmission among HIV-discordant couples in Rakai, Uganda
Serwadda, D; Makumbi, FE; Reynolds, SJ; Gray, RH; Kiwanuka, N; Laeyendecker, O; Quinn, TC; Wawer, MJ; Shepherd, J; Robb, M; Kigozi, G; Kagaayi, J
AIDS, 23(18): 2479-2484.
PDF (308) | CrossRef
Back to Top | Article Outline

vaccines; HIV vaccines; willingness; Rakai

© 2004 Lippincott Williams & Wilkins, Inc.